| Objective: To investigate the cost-effectiveness of sulfonylureas in the treatment of type 2 diabetes mellitus(T2DM), so as to provide reference for clinicians to choose rational drug use. Methods: A total of 180 patients with type 2 diabetes treated in People's Hospital of Kangping County from August 2017 to December 2019 were selected as the research objects. According to the random number table method, the subjects were divided into three groups-group A, group B and group C(60 cases in each group), Group A was treated with metformin sustained-release tablets combined with glimepiride, Group B was treated with acarbose combined with glimepiride, Group C was treated with rosiglitazone combined with glimepiride. The effective rate, C/E value, cost and blood glucose control of the three groups were compared. Results: The total effective rate of group C(93.33%)was higher than that of group A and group B, but the difference was not statistically significant(P＞0.05); the percentage of blood glucose decrease in group C was higher than that in group A and group B, the difference was statistically significant(P＜0.05); the C/E value(23.25), the average blood glucose decrease rate(35.72%)and the cost(846.20yuan) in group C were higher than those in group A and group B. The C/E value(18.86)and cost(485.52yuan) in group B were higher than those in group A, but the average blood glucose decrease rate(26.24%)was compared with group A, the difference was not statistically significant(P＞0.05). Conclusion: The three combined drug regimens can effectively treat type 2 diabetes, but the cost-effectiveness of metformin sustained-release tablets combined with glimepiride is the best, which is worthy of clinical application. |
